Can AI Accelerate Precision Medicine?
Click the menu icon in the upper right of the video to select 1-6 in the playlist.
Recent progress in artificial intelligence has been touted as the solution for many of the challenges facing clinicians and patients in diagnosing and treating disease. Concurrently, there is a growing concern about the biases and lapses caused by the use of algorithms that are incompletely understood. Yet precision medicine* requires sifting through millions of individuals measured with thousands of variables: an analysis that defeats human cognitive capabilities. In this conference, we ask the question whether AI can be used effectively to accelerate precision medicine in ways that are safe, non-discriminatory, affordable and in the patient’s best interest. To answer the question, we have three panels and three keynote speakers. The first panel addresses the question of Policy and the Patient: Who’s in Control? We will review the intersection of consent, transparency and regulatory oversight in this very dynamic ethical landscape.The second panel, Is there Value in Prediction?, addresses a widely-shared challenge in medicine, which is to predict the patient’s future, and most importantly, their response to therapy. Can AI actually make a contribution in this area? The third panel on Hyperindividualized Treatments asks the question of how to think about a future that is fast becoming the present, where therapy is “hyper-individualized,” so it is the very uniqueness of your genome that determines your therapy. As always, we have a patient representative for our opening keynote, Matt Might, who returns to this annual conference to discuss the development of an algorithm for conducting precision medicine, through the lens of a personal story: discovering that his child was the first case of a new, ultra-rare genetic disorder. Our midday keynote by Professor Regina Barzilay will guide us through a personal journey from diagnosis to an exciting agenda to increase precision in discovery of cancer treatments and improved delivery of cancer care. Our closing keynote will be given by Jim Tananbaum of Foresite Capital. He is one of the original investors and drivers of Insitro, an AI company that seeks to become a full service therapeutic engine. We hope this conference will create a larger consensus around these still controversial and mostly uncharted questions.
Tuesday, June 18, 2019, 8:00 am – 4:45 pm ET
|Time||Topic & Speaker(s)|
|8:00-9:00 AM||Continental Breakfast and Check-in|
|9:00-9:15 AM||Welcome — Isaac Kohane, Harvard Medical School|
|9:15-9:30 AM||Opening Remarks — George Daley, Dean, Harvard Medical School|
|9:30-10:15 AM||Keynote — Matt Might, Hugh Kaul Precision Medicine Institute at UAB|
|10:15-11:30 AM||PANEL 1 — Policy and the Patient: Who's in Control?
|12:15-1:30 PM||PANEL 2 — Is There Value in Prediction?
|1:30-2:15 PM||Keynote — Regina Barzilay, Massachusetts Institute of Technology|
|2:30-3:45 PM||PANEL 3 — Hyperindividualized Treatments (Moderator: David Shaywitz)
|3:45-4:30 PM||Closing Keynote — Jim Tananbaum, Foresite Capital|
|4:30-4:45 PM||Closing Remarks — Isaac Kohane, Harvard Medical School|
*What do we mean by “precision medicine”? From the perspective of one of the members of the National Academy of Sciences committee that wrote the report, we mean taking an explicit multidimensional view of patients: not just one data modality such as genomics or environmental exposure. We argue that this perspective allows for more precise matching of humans to disease states (diagnosis), future disease states (prognosis) and appropriate therapies.
Conference sponsored by DBMI, Amazon Web Services and Medidata Solutions | Acorn AI.